Investor Relations
Corporate Profile
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
- Change
Minimum 15 minutes delayed. Source:
News Releases
Oct 29
2024
2024
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Learn More >
Sep 30
2024
2024
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Learn More >
Sep 26
2024
2024
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
Learn More >
Aug 08
2024
2024
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Learn More >
Aug 07
2024
2024
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
Learn More >
Jul 31
2024
2024
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
Learn More >
Jul 01
2024
2024
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Learn More >
Jun 20
2024
2024
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Learn More >
May 23
2024
2024
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Learn More >
May 13
2024
2024
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Learn More >
Events
May 28, 2024 at 12:30 PM EDT
Aug 7, 2024 at 5:00 PM EDT